B. Hibner

发表

Discovery of a novel Raf kinase inhibitor.

G. Bollag, J. Lyons, S. Wilhelm, 2001, Endocrine-related cancer.

Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent.

Xiao-Gao Liu, Barbara Hibner, Joel Renick, 2004, Bioorganic & medicinal chemistry letters.

Dominant negative mutants of mitogen-activated protein kinase pathway.

M. J. Arboleda, J. Lyons, B. Hibner, 2001, Methods in enzymology.

Abstract 3880: In vivo activities of TP-2846: a novel tetracycline antileukemia agent

A. Chakravarty, B. Hibner, Xiao-yi Xiao, 2019 .

Shared T cell-defined antigens on independently derived tumors.

J. Collins, B. Hibner, D. Sahasrabudhe, 1993, Journal of immunology.

CHIR-124, a Novel Potent Inhibitor of Chk1, Potentiates the Cytotoxicity of Topoisomerase I Poisons In vitro and In vivo

E. Moler, G. Schwartz, M. Embry, 2007, Clinical Cancer Research.

Tezacitabine enhances the DNA-directed effects of fluoropyrimidines in human colon cancer cells and tumor xenografts.

E. Moler, Fernando Salangsang, B. Hibner, 2007, Biochemical pharmacology.

Sequence identity in an early chorion multigene family is the result of localized gene conversion.

T. Eickbush, W. Burke, B. Hibner, 1991, Genetics.

Endocrine-Related Cancer ( 2001 ) 8 219 – 225 Discovery of a novel Raf kinase inhibitor

G. Bollag, J. Lyons, S. Wilhelm, 2001 .

Organization and expression of three genes from the silkmoth early chorion locus.

T. Eickbush, W. Burke, B. Hibner, 1988, Developmental biology.

MET Tyrosine Kinase Inhibition Enhances the Antitumor Efficacy of an HGF Antibody

J. Lawson, P. Vincent, K. Okada, 2017, Molecular Cancer Therapeutics.

A Potent Nonpeptidic Matrix Metalloproteinase Inhibitor

S. Wilhelm, B. Hibner, R. Humphrey, 2001 .

Perspectives on molecular and anatomical imaging in drug discovery.

Rob Robertson, Matthew D Silva, Mac Johnson, 2005, BioTechniques.